Adicet scores the first hit for gamma-delta
Three of four lymphoma patients given ADI-001 go into remission, and Adicet soars 30%.
Spac listings slow as the hunt for deals continues
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
Immatics takes up the Spac baton
First signals of efficacy, at doses thought to have been sub-therapeutic, send the Spac-listed group up 30%.
The reckoning begins for biotech-focused Spacs
The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.
More biotechs test the third way to market
Formation of Spacs – special-purpose acquisition companies – is surging, but will fierce competition for deals hurt performance?
